Novel aspects of factor XIII deficiency

Current Opinion in Hematology

Volumn 18, Issue 5, 2011, Pages 366-372

  Muszbek, László ^a,b   Bagoly, Zsuzsa ^a   Cairo, Andrea ^c   Peyvandi, Flora ^c  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

autoantibody; bleeding diathesis; factor XIII; factor XIII deficiency; replacement therapy

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 13B; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 13; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ABORTION; BLEEDING; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CLINICAL FEATURE; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FETUS WASTAGE; FIBRINOLYSIS; GENE MUTATION; HUMAN; LABORATORY DIAGNOSIS; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW;

FACTOR XIII DEFICIENCY; HUMANS;

EID: 80051781189     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e3283497e3e     Document Type: Review

References (39)

1. Kasahara K, Souri M, Kaneda M, et al. Impaired clot retraction in factor XIII A subunit-deficient mice. Blood 2010;115:1277-1279. Platelet abnormality in factor XIII-deficient mice.
2. Magwenzi SG, Ajjan RA, Standeven KF, et al. Factor XIII supports platelet activation and enhances thrombus formation by matrix proteins under flow conditions. J Thromb Haemost 2011;9:820-833. Impaired platelet function in FXIII deficiency.
3. Jayo A, Conde I, Lastres P, et al. New insights into the expression and role of platelet factor XIII-A. J Thromb Haemost 2009;7:1184-1191.
4. Muszbek L, Bagoly Z, Bereczky Z, Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc Hematol Agents Med Chem 2008;6:190-205.
5. Komaromi I, Bagoly Z, Muszbek L Factor XIII: novel structural and functional aspects. J Thromb Haemost 2011;9:9-20. A most recent review on the structure and function of FXIII.
6. Inbal A, Lubetsky A, Krapp T, et al. Impaired wound healing in factor XIII deficient mice. Thromb Haemost 2005;94:432-437. (Pubitemid 41122500)
7. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006;4:19-25.
8. Asahina T, Kobayashi T, Okada Y, et al. Maternal blood coagulation factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000;21:388-393. (Pubitemid 30364873)
9. Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstet Gynecol Surv 2007;62:255-260. (Pubitemid 46555920)
10. Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000;55:103-108. (Pubitemid 30078400)
11. Koseki-Kuno S, Yamakawa M, Dickneite G, Ichinose A. Factor XIII A subunitdeficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages. Blood 2003;102:4410-4412. (Pubitemid 37494103)
12. Muszbek L, Bagoly Z. Fibrin formation disorders and pregnancy loss. Thromb Res 2007;119:S69-S70.
13. Inbal A, Muszbek L Coagulation factor deficiencies and pregnancy loss. Semin Thromb Hemost 2003;29:171-174. (Pubitemid 36458196)
14. Karimi M, Bereczky Z, Cohan N, Muszbek L Factor XIII deficiency. Semin Thromb Hemost 2009;35:426-438.
15. Mahmoodi M, Peyvandi F, Afrasiabi A, et al. Bleeding symptoms in heterozygous carriers of inherited coagulation disorders in southern Iran. Blood Coagul Fibrinolysis 2011 [Epub ahead of print]. This study was suggested since bleeding symptoms in heterozygous subjects were reported and few data on heterozygotes are available in the literature.
16. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001;86:57-65. (Pubitemid 32663937)
17. Kohler HP, Ichinose A, Seitz R, et al. Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 2011. doi: 10.1111/j.1538-7836.2011. 04315.x. The recommenation of ISTH SSC on the diagnosis and classification of FXIII deficiencies, and supplementary material with methodological aspects and commercially available reagent kits.
18. Morange P, Trigui N, Frere C, et al. Molecular characterization of a novel mutation in the factor XIII a subunit gene associated with a severe defect: importance of prophylactic substitution. Blood Coagul Fibrinolysis 2009;20:605-606.
19. Ivaskevicius V, Biswas A, Bevans C, et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010;95:956-962. Novel FXIII-A mutations; their structural consequences were explored by molecular modeling.
20. Anwar R, Langlois S. The Arg703Trp missense mutation in F13A1 is a de novo event. Br J Haematol 2009;146:118-120.
21. Louhichi N, Medhaffar M, Hadjsalem I, et al. Congenital factor XIII deficiency caused by two mutations in eight Tunisian families: molecular confirmation of a founder effect. Ann Hematol 2010;89:499-504. The mutation is due to an ancient founder effect. The first well established founder effect among FXIII-A deficiencies.
22. El Mahmoudi H, Amor MB, Gouider E, et al. Small insertion (c.869insC) within F13A gene is dominant in Tunisian patients with inherited FXIII deficiency due to ancient founder effect. Haemophilia 2009;15:1176-1179.
23. Ivaskevicius V, Biswas A, Loreth R, et al. Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects: results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia 2010;16:675-682. Description of 12 novel FXIII-B mutations, one in homozygous form.
24. Ichinose A, Souri M. As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 2011;105:10-11. Eleven new cases of FXIII deficiencies due to autoantibodies against FXIII-A and one due to an autoantibody against FXIII-B.
25. Luo Y, Zhang G, Zuo W, et al. Acquired factor XIII inhibitor in monoclonal gammopathy of undetermined significance: characterization and cross-linked fibrin ultrastructure. Ann Hematol 2010;89:833-834. Report on a neutralizing autoantibody against FXIII-A.
26. Luo YY, Zhang GS. Acquired factor XIII inhibitor: clinical features, treatment, fibrin structure and epitope determination. Haemophilia 2011 [Epub ahead of print]. A case report on a FXIII-A deficiency due to a neutralizing autoantibody.
27. Ishida F, Okubo K, Ito T, et al. Spontaneous regression of the inhibitor against the coagulation factor XIIIA subunit in acquired factor XIII deficiency. Thromb Haemost 2010;104:1284-1285.
28. Ajzner E, Schlammadinger A, Kerenyi A, et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood 2009;113:723-725.
29. Lawrie AS, Green L, Mackie IJ, et al. Factor XIII: an under diagnosed deficiency - are we using the right assays? J Thromb Haemost 2010;8:2478-2482. Adaptation of ammonia release FXIII assays to automated coagulometers. Demonstration of the importance of blank deduction in the low range of FXIII activity.
30. Ajzner E, Muszbek L Kinetic spectrophotometric factor XIII activity assays: the subtraction of plasma blank is not omissible [corrected]. J Thromb Haemost 2004;2:2075-2077.
31. Todd T, Perry DJ. A review of long-term prophylaxis in the rare inherited coagulation factor deficiencies. Haemophilia 2010;16:569-583. This study reports guidelines for the treatment of patients affected with FXIII deficiency.
32. Castaman G. Prophylaxis of bleeding episodes and surgical interventions in patients with rare inherited coagulation disorders. Blood Transfus 2008;6(Suppl 2):s39-s44.
33. Bolton-Maggs PH, Perry DJ, Chalmers EA, et al. The rare coagulation disorders: review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004;10:593-628. (Pubitemid 39317772)
34. Lusher J, Pipe SW, Alexander S, Nugent D. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010;16:316-321.
35. Gootenberg JE. Factor concentrates for the treatment of factor XIII deficiency. Curr Opin Hematol 1998;5:372-375. (Pubitemid 28521503)
36. Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008;14:1190-1200.
37. Dreyfus M, Barrois D, Borg JY, et al. Successful long-term replacement therapy with FXIII concentrate (Fibrogammin ((R)) P) for severe congenital factor XIII deficiency: a prospective multicentre study. J Thromb Haemost 2011 [Epub ahead of print]. This is the first prospective cohort study reporting a systematic longitudinal followup of patients with severe FXIII deficiency, receiving FXIII replacement therapy with FXIII concentrate.
38. Lovejoy AE, Reynolds TC, Visich JE, et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006;108:57-62.
39. Inbal A, Oldenburg J, Carcao M, et al. Recombinant factor XIII, safe and novel treatment for congenital factor XIII deficiency (ASH Annual Meeting Abstracts). Blood 2010;116:20. This study reports information about efficacy and safety of a novel recombinant FXIII.